Top Markets
#1 MowCat MowCat +26.91%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +17.61%
#3 Versatize Coin Versatize Coin +16.67%
#4 QuantixAI QuantixAI +12.95%
#5 Pons Pons +12.04%
#6 Wrapped NXM Wrapped NXM +10.13%
#7 Nesa Nesa +9.89%
#8 StonkBroker StonkBroker +9.58%
#9 Collector Crypt Collector Crypt +8.81%
#10 Siren Siren +8.20%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Sunho Biologics, Inc. Sunho Biologics, Inc.

Sunho Biologics, Inc.

2898
Rank in Stocks #20679
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering,... Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Share Price
$0.81744861
Last synced: 2026-04-02
Market Cap
$124.61M
Change (1 day)
0.00%
Change (1 year)
-7.82%
Country
CN
Trade Sunho Biologics, Inc. (2898)

Category

Healthcare
P/E ratio for Sunho Biologics, Inc. (2898)
P/E ratio as of 2026 TTM: 0
According to Sunho Biologics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Sunho Biologics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.